
Ventyx Biosciences, Inc.
VTYXNASDAQHealthcare
$14.00
+$0.00(+0.00%)
Market Cap$1.0B
P/E Ratio—
52W High$25
52W Low$0.783
Ventyx Biosciences, Inc.(VTYX)· 损益表
年度 / 季度 / TTM 视图 · SEC 10-K 与 10-Q(经 FMP 聚合)· 可在下方切换周期与 M/B/T 单位。
FMP · VTYX · 截至 2026-06-08
财务报表
Revenue · Gross Profit · Net Income
| Breakdown | 2024-12 | 2023-12 | 2022-12 | 2021-12 | 2020-12 |
|---|---|---|---|---|---|
| Revenue | |||||
| Revenue | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Cost of Revenue | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Gross Profit | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Gross Margin %(computed) | — | — | — | — | — |
| Operating Expenses | |||||
| R&D Expenses | $0.12B | $0.18B | $0.09B | $0.06B | $0.01B |
| G&A Expenses | $0.03B | $0.03B | $0.03B | $0.01B | $0.00B |
| Total Operating Expenses | $0.15B | $0.21B | $0.11B | $0.07B | $0.01B |
| Operating Income | ($0.15B) | ($0.21B) | ($0.11B) | ($0.07B) | ($0.01B) |
| Operating Margin %(computed) | — | — | — | — | — |
| Interest Income | $0.01B | $0.02B | $0.00B | $0.00B | $0.00B |
| Interest Expense | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Income Before Tax | ($0.14B) | ($0.19B) | ($0.11B) | ($0.08B) | ($0.03B) |
| Income Tax Expense | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Net Income | ($0.14B) | ($0.19B) | ($0.11B) | ($0.08B) | ($0.03B) |
| Net Margin %(computed) | — | — | — | — | — |
| Per Share & EBITDA | |||||
| EPS (Basic) | $-1.97 | $-3.30 | $-2.06 | $-1.69 | $-0.56 |
| Wtd Avg Shares | 0.07B | 0.06B | 0.05B | 0.05B | 0.05B |
| EBITDA | ($0.15B) | ($0.21B) | ($0.11B) | ($0.08B) | $0.00B |
| EBITDA Margin %(computed) | — | — | — | — | — |
数据来源:Financial Modeling Prep · 最后更新:2026-06-08 · USD · B
深入了解Ventyx Biosciences, Inc.
关于Ventyx Biosciences, Inc.(VTYX)损益表
Ventyx Biosciences, Inc.(VTYX)损益表数据来源于SEC Form 10-K及10-Q申报文件。2024财年,VTYX实现营收$0.00B,毛利润$0.00B(毛利率—),净利润($0.14B)(净利率—)。
常见问题
VTYX · 4 问Ventyx Biosciences, Inc.(VTYX)2024财年营收为$0.00B,同比down—%。
VTYX revenueVTYX salesannual revenue YoYincome statement
· Source: FMP /stable/income-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-08